U.S. Markets closed

How This Highly Rated Biotech Stock Added To Its Meteoric Run

ALLISON GATLIN
How This Highly Rated Biotech Stock Added To Its Meteoric Run

Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments. Its lead program is in acute myeloid leukemia.